Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-05
1999-11-23
Degen, Nancy
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435366, 536 245, A61K 3170, C07H 2104, C12N 508
Patent
active
059900881
ABSTRACT:
The present invention relates to a method to treat Kaposi's sarcoma (KS), and particularly, human immunodeficiency virus associated KS through the administration of antisense oligonucleotides complementary to basic fibroblast growth factor RNA.
REFERENCES:
patent: 5585479 (1996-12-01), Hoke et al.
Morrison (1991) Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes. J. Biol. Chem. 266:728-734, Jan. 1991.
Rojanasakul (1996) Antisense oligonucleotide therapeutics: drug delivery and targeting. Adv. Drug Delivery Rev. 18:115-131, 1996.
New England Journal of Medicine (1982); vol. 306, No. 4, pp. 248-252.
Abraham et al., Science, "Nucleotide Sequence of a Bovine Clone Enclding the Angiogenic Protein, Basic Fibroblast Growth Factor", 233: 545-548.
Agarwal et al., Nucleic Acids Research (1979), vol. 6, No. 4, pp. 3009-3025.
Albini et al., Cancer Research (1987); "A Rapid in Vitro Assay for Quantitating the Invasive Potential of Tumor Cells"; 47: 3239-3245.
Barillari et al., Journal of Immunology (1992); "Effects of Cytokines from Activated Immune Cells on Vascular Cell Growth and HIV-1 Gene Expression"; vol. 149, No. 11, pp. 3727-3734.
Bayever et al., Antisense Research and Development; "Guest Editorial: Systemic Human Antisense Therapy Begins"; 2:109-110 (1992).
Becker et al., EMBO Journal; "Proliveration of Human Malignant Melanomas is Inhibited by Antisense Oligodeoxynucleotides Targeted Against Basic Fibroblast Growth Factor"; vol. 8, No. 12, pp. 3685-3691 (1989).
Burgess et al., Annu. Rev. Biochem; The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins; 58:575-606 (1989).
Dagle et al., Nucleic Acids Research; "Targeted Degradation of mRNA in Xenopus Oocytes and Embryos Directed by Modified Oligonucleotides: Studies of An2 and Cyclin in Embryogenesis"; vol. 18, No. 16.
Ensoli et al., Science; "AIDS--Kaposi's Sarcoma-Derived Cells Express Cytokines with Autocrine and Paracrine Growth Effects"; 243:223-226.
Ensoli et al., Hematol. Oncol. Clin. No. Am.; "Pathogenesis of AIDS-Associated Kaposi's Sarcoma": 5:281 (1991).
Ensoli et al., Immunol. Rev.; "Cytokines and Growth Factors in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma"; 127:147-155.
Ensoli et al., Journal of Virology; "Release, Uptake, and Effects of Extracellular Human Immunodeficiency Virus Type 1 Tat Protein on Cell Growth and Viral Transactivation", 67:277-287.
Folkman et al., Nature; "Angiogenesis in vitro"; 288:551-556.
Folkman et al., Science; "Angiogenic Factors"; 235:442-447.
Friedman-Kein, Am. Acad. Dermatology; "Disseminated Kaposi's Sarcoma Syndrome in Young Homosexual Men"; 5:468-471.
Gottlieb et al., Human Pathology; "Kaposi's Sarcoma: An Extensively Disseminated Form in Young Homosexual Men"; 13:882-892.
Haverkos et al., N. Eng. J. Med.; 312:1518 (1995).
Ingber et al., Nature; "Synthetic Analogues of Fumagillin that Inhibit Angiogenesis and Suppress Tumour Growth"; 348:555-557.
Inoue et al., FEBS Letters; "Sequence-Dependent Hydrolysis of RNA Using Modified Oligonucleotide Splints and RNase H"; 215:327-330 (1987).
LaPlance et al., Nuc. Acids Res.; "Phosphorothioate-Modified Oligodeoxyribonucleotides"; 14:9081-9093.
Loke et al., Proc. Natl. Acad. Sci. USA; "Characterization of Oligonucleotide Transport into Living Cells"; 86:3474-3478.
Inoue et al., Nucleic Acids Research; "Synthesis and Hybridization Studies on Two Complementary Nona (2'-O-methyl) Ribonucleotides"; 15:6131.
McNutt et al., Am. J. Pathol.; "Early Lesions of Kaposi's Sarcoma in Homosexual Men"; 111:62-77.
Miles et al., Proc. Natl. Acad. Sci. USA; "AIDS Kaposi Sarcoma-Derived Cells Produce and Respond to Interleukin 6"; 87:4068-4072.
Roth et al., Oncogene; "Depletion of PDGF from Serum Inhibits Growth of AIDS-Related and Sporadic Kaposi's Sarcoma Cells in Culture"; 4:483.
Safai et al., Annals of Internal Medicine; "The Natural History of Kaposi's Sarcoma in the Acquired Immunodeficiency Sydrome" 103:744-750.
Salahuddin et al., Science; "Angiogenic Properties of Kaposi's Sarcoma-Derived Cells After Long-Term Culture in Vitro"; 242:430-433.
Sarin et al., Proc. Natl. Acad. Sci. USA, "Inhibition of Acquired Immunodeficiency Syndrome Virus by Oligodeoxynucleoside Methylphosphonates"; 85:7448-7451.
Shakin et al., J. Biol. Chem.; "Destablization of Messenger RNA/Complementary DNA Duplexes by the Elongatng 80 S Ribonsome"; 261:10618.
Stec et al., J. Am. Chem. Soc.; "Automated Solid-Phase Synthesis, Separation, and Stereochemistry of Phosphorothioate Analogues of Oligodeoxyribonucleotides"; 106:6077-6079.
Sturzl et al., Proc. Natl. Acad. Sci. USA; "Expression of Platelet-Derived Growth Factor and its Receptor in AIDS-Related Kaposi Sarcoma in Vivo Suggests Paracrine and Autocrine Mechanisms of Tumor Maintenance"; 89:7046.
Thompson et al., Cancer Res.; "Supernatants of Acquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma Cells Induce Endothelial Cell Chemotaxis and Invasiveness"; 51:2670-2676.
Thompson et al., Science; "Site-Directed Neovessel Formation in Vivo"; 241:1349-1352.
Uhlmann et al., Chemical Review; "Antisense Oligonucleotides; A New Therapeutic Principle"; 90:543-584.
Weindel et al., Biochemical and Biophysical Research Communications; "AIDS-Associated Kaposi's Sarcoma Cells in Culture Express Vascular Endothelial Growth Factor"; 183:1167-1174.
Xerri et al., Am. J. Pathol.; "Fibroblast Growth Factor Gene Expression in AIDS--Kaposi's Sarcoma Detected by In Situ Hybridization"; 138:9-15.
Morrison, Suppression of Basic Fibroblast Growth Factor Expression by Antisense Oligodeoxynucleotides Inhibits the Growth of Transformed Human Astrocytes, The Journal of Biological Chemistry, 266:728-734, 1991.
Ensoli Barbara
Gallo Robert C.
Degen Nancy
Schwartzman Robert
The United States of America as represented by the Department of
LandOfFree
Method for treating kaposi's sarcoma with antisense oligonucleot does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating kaposi's sarcoma with antisense oligonucleot, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating kaposi's sarcoma with antisense oligonucleot will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1221974